The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome

Exclusion Criteria

• •1. Patients with bypass graft or in-stent restenosis at the site of PCI.
• •2. Patients who received PCI in the past on the lesion where the evaluation of coronary plaque volume is planned.
• •3. Patients who had plaques in a non-culprit site and might receive PCI during the treatment period.
• •4. Patients receiving lipid-lowering drugs (statins, fibrates, probucol, nicotinic acid or cholesterol absorption inhibitors).
• •5. Patients with familial hypercholesterolemia.
• •6. Patients with cardiogenic shock.
• •7. Patients receiving cyclosporine.
• •8. Patients with any allergy to Ezetimibe.
• •9. Patients with hepatobiliary disorders.
• •10. Pregnant women, women suspected of being pregnant, or lactating women.
• •11. Patients with renal disorders or undergoing dialysis.
• •12. Patients who are ineligible in the opinion of the investigator.